Canada - English - Health Canada

jamp pharma corporation - prasugrel (prasugrel hydrochloride) - tablet - 10mg - prasugrel (prasugrel hydrochloride) 10mg - platelet aggregation inhibitors

United States - English - NLM (National Library of Medicine)

a-s medication solutions - prasugrel hydrochloride (unii: g89jq59i13) (prasugrel - unii:34k66tbt99) - prasugrel tablets are indicated to reduce the rate of thrombotic cardiovascular (cv) events (including stent thrombosis) in patients with acute coronary syndrome (acs) who are to be managed with percutaneous coronary intervention (pci) as follows: - patients with unstable angina (ua) or non-st-elevation myocardial infarction (nstemi). - patients with st-elevation myocardial infarction (stemi) when managed with primary or delayed pci. prasugrel tablets have been shown to reduce the rate of a combined endpoint of cardiovascular death, nonfatal myocardial infarction (mi), or nonfatal stroke compared to clopidogrel. the difference between treatments was driven predominantly by mi, with no difference on strokes and little difference on cv death [see clinical studies ( 14)] . prasugrel tablets are contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage [see warnings and precautions (

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - prasugrel hydrochloride (unii: g89jq59i13) (prasugrel - unii:34k66tbt99) - prasugrel 10 mg - effient™ is indicated to reduce the rate of thrombotic cardiovascular (cv) events (including stent thrombosis) in patients with acute coronary syndrome (acs) who are to be managed with percutaneous coronary intervention (pci) as follows: - patients with unstable angina (ua) or non-st-elevation myocardial infarction (nstemi). - patients with st-elevation myocardial infarction (stemi) when managed with primary or delayed pci. effient has been shown to reduce the rate of a combined endpoint of cardiovascular death, nonfatal myocardial infarction (mi), or nonfatal stroke compared to clopidogrel. the difference between treatments was driven predominantly by mi, with no difference on strokes and little difference on cv death [see clinical studies (14)] . it is generally recommended that antiplatelet therapy be administered promptly in the management of acs because many cardiovascular events occur within hours of initial presentation. in the clinical trial that established the efficacy of effient, ef

New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - prasugrel hydrochloride 5.49mg - film coated tablet - 5 mg - active: prasugrel hydrochloride 5.49mg excipient: croscarmellose sodium glycerol hypromellose iron oxide yellow lactose magnesium stearate mannitol microcrystalline cellulose purified talc titanium dioxide - effient, co-administered with aspirin, is indicated for the prevention of atherothrombotic events (myocardial infarction, stroke and cardiovascular death) in patients with acute coronary syndromes (moderate to high risk unstable angina (ua), non st-segment elevation myocardial infarction (nstemi) or st-segment elevation myocardial infarction (stemi)) who are to undergo percutaneous coronary intervention (pci).

United States - English - NLM (National Library of Medicine)

a-s medication solutions - prasugrel hydrochloride (unii: g89jq59i13) (prasugrel - unii:34k66tbt99) - prasugrel tablets are indicated to reduce the rate of thrombotic cardiovascular (cv) events (including stent thrombosis) in patients with acute coronary syndrome (acs) who are to be managed with percutaneous coronary intervention (pci) as follows: - patients with unstable angina (ua) or non-st-elevation myocardial infarction (nstemi). - patients with st-elevation myocardial infarction (stemi) when managed with primary or delayed pci. prasugrel tablets have been shown to reduce the rate of a combined endpoint of cardiovascular death, nonfatal myocardial infarction (mi), or nonfatal stroke compared to clopidogrel. the difference between treatments was driven predominantly by mi, with no difference on strokes and little difference on cv death [see clinical studies (14)] . prasugrel is contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage [see warnings and precautions (5.1) and adverse reactions (6.1)] . prasugrel is contraindicated in patients with a histo

Singapore - English - HSA (Health Sciences Authority)

eli lilly (singapore) pte ltd - prasugrel hydrochloride 5.49mg eqv prasugrel - tablet, film coated - 5mg/tablet - prasugrel hydrochloride 5.49mg eqv prasugrel 5 mg

Malta - English - Malta Medicines Authority

vocate pharmaceuticals s.a 150, gounari str, 166 74 glyfada, athens, greece - prasugrel - film-coated tablet - prasugrel 5 mg - antithrombotic agents

Malta - English - Malta Medicines Authority

vocate pharmaceuticals s.a 150, gounari str, 166 74 glyfada, athens, greece - prasugrel - film-coated tablet - prasugrel 10 mg - antithrombotic agents

European Union - English - EMA (European Medicines Agency)

mylan pharmaceuticals limited - prasugrel besilate - myocardial infarction; acute coronary syndrome; angina, unstable - antithrombotic agents - prasugrel mylan, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndrome (i.e. unstable angina, non-st segment elevation myocardial infarction [ua/nstemi] or st segment elevation myocardial infarction [stemi]) undergoing primary or delayed percutaneous coronary intervention (pci).

Canada - English - Health Canada

eli lilly canada inc - prasugrel (prasugrel hydrochloride) - tablet - 10mg - prasugrel (prasugrel hydrochloride) 10mg - platelet aggregation inhibitors